18 October 2021: OIA response | Correspondence about Dexcom continuous glucose monitors, Tandem t:slim X2 insulin pumps, and the Dexcom Inc acquisition

18 October 2021 

Dear [name and contact details withheld] 

Request for information 

Thank you for your request dated 5 August 2021 under the Official Information Act 1982 (OIA) for information relating to correspondence between Pharmac and NZMS. 

Further to our correspondence of 24 September 2021, please find a copy of the correspondence related to your request attached with this letter. 

A reminder that we have decided to redact a small amount of information, or withhold some correspondence, from the document provided as we consider this is necessary to:

  • protect the privacy of natural persons (section 9(2)(a));
  • protect information where the making available of the information would be likely to unreasonably prejudice the commercial position of the person who supplied or who is the subject of the information (section 9(2)(b)(ii));
  • protect information which is subject to an obligation of confidence or which any person has been or could be compelled to provide under the authority of any enactment, where the making available of the information would be likely to prejudice the supply of similar information, or information from the same source, and it is in the public interest that such information should continue to be supplied (section 9(2)(ba)(i));
  • enable Pharmac to carry on, without prejudice or disadvantage, negotiations, including commercial negotiations (section 9(2)(j)). 

You have the right, by way of complaint under section 28(3) of the OIA to an Ombudsman, to seek an investigation and review of our decision.

We trust that this information answers your queries. We are making our information more freely available, so we now publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this. 

Yours sincerely 

Rachel Read
Manager, Policy and Government Services